# Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

> **NCT03581942** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Copanlisib

## Key facts

- **NCT ID:** NCT03581942
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2026-02-05
- **Final completion:** 2026-02-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03581942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03581942, "Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03581942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*